Cargando…
PPAR-Gamma Agonist Pioglitazone Reduced CD68+ but Not CD163+ Macrophage Dermal Infiltration in Obese Psoriatic Patients
BACKGROUND: Macrophages are of great importance in the development of obesity and psoriasis. Signaling via PPAR-γ in certain macrophage populations is associated with M2-like features and anti-inflammatory profile. In this research, we evaluated the anti-inflammatory action of pioglitazone by the im...
Autores principales: | Yemchenko, Ya. O., Shynkevych, V. I., Ishcheikin, K. Ye, Kaidashev, I. P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211254/ https://www.ncbi.nlm.nih.gov/pubmed/32411188 http://dx.doi.org/10.1155/2020/4548012 |
Ejemplares similares
-
PPAR-γ Agonist Pioglitazone Restored Mouse Liver mRNA Expression of Clock Genes and Inflammation-Related Genes Disrupted by Reversed Feeding
por: Fedchenko, T., et al.
Publicado: (2022) -
Prophylaxis of decidual CD68(+)/CD163(+) macrophage disbalance in extracorporeal fertilized women
por: Likhachov, Volodymyr, et al.
Publicado: (2023) -
PPARG agonist pioglitazone influences diurnal kidney medulla mRNA expression of core clock, inflammation‐, and metabolism‐related genes disrupted by reverse feeding in mice
por: Izmailova, Olga, et al.
Publicado: (2022) -
The Clinical Significance of the CD163+ and CD68+ Macrophages in Patients with Hepatocellular Carcinoma
por: Kong, Ling-Qun, et al.
Publicado: (2013) -
High Infiltration of CD68(+)/CD163(−) Macrophages Is an Adverse Prognostic Factor after Neoadjuvant Chemotherapy in Esophageal and Gastric Adenocarcinoma
por: Svensson, Maria C., et al.
Publicado: (2022)